| scholarly article | Q13442814 |
| P50 | author | Jamie M Aye | Q88548481 |
| Gregory K Friedman | Q42170568 | ||
| Laura L Stafman | Q88548479 | ||
| P2093 | author name string | Elizabeth A Beierle | |
| Blake P Moore | |||
| Elizabeth Mroczek-Musulman | |||
| Jerry E Stewart | |||
| Evan F Garner | |||
| Adele P Williams | |||
| P2860 | cites work | NIH Image to ImageJ: 25 years of image analysis | Q23319322 |
| CIP2A inhibits PP2A in human malignancies | Q24319683 | ||
| Molecular subgroups of medulloblastoma: the current consensus | Q24615271 | ||
| Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer | Q27853204 | ||
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 | ||
| FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels | Q28541065 | ||
| FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model | Q29248124 | ||
| FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells | Q31952928 | ||
| FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells | Q40140527 | ||
| FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase | Q40317574 | ||
| FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation | Q40528059 | ||
| Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment | Q40644323 | ||
| Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. | Q40745321 | ||
| Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis | Q40749272 | ||
| Promising new therapies in the treatment of advanced ovarian cancer | Q40989128 | ||
| Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. | Q42739353 | ||
| Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts | Q42809089 | ||
| Fingolimod confers neuroprotection through activation of Rac1 after experimental germinal matrix hemorrhage in rat pups | Q46079105 | ||
| Activation of Akt and Erk pathways in medulloblastoma | Q48397343 | ||
| FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. | Q54334399 | ||
| Reduced expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the Aalpha and Abeta subunit genes | Q74415871 | ||
| CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis | Q34138056 | ||
| Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
| FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma | Q34269804 | ||
| Medulloblastoma: clinical and biologic aspects | Q34364285 | ||
| Rapamycin: an anti-cancer immunosuppressant? | Q34436339 | ||
| FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling | Q34459845 | ||
| Oral fingolimod (FTY720) for relapsing multiple sclerosis | Q34565985 | ||
| PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects | Q35552005 | ||
| Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival | Q35642231 | ||
| Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma | Q35845241 | ||
| FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia | Q35945171 | ||
| FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma | Q36384629 | ||
| Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses | Q36493813 | ||
| Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis | Q36602177 | ||
| Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma | Q36655904 | ||
| Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
| Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings | Q37181682 | ||
| Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke | Q37209163 | ||
| Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts | Q38263942 | ||
| Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells | Q38622060 | ||
| SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line | Q38699543 | ||
| Oncogenic Role of SET/I2PP2A for Gynecologic Cancers | Q38738002 | ||
| FTY720-induced enhancement of autophagy protects cells from FTY720 cytotoxicity in colorectal cancer | Q38785633 | ||
| Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer. | Q38869675 | ||
| FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells | Q38879206 | ||
| Childhood medulloblastoma. | Q38885202 | ||
| Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer | Q38937332 | ||
| FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system | Q39114974 | ||
| Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models | Q39242149 | ||
| Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation | Q39438493 | ||
| FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. | Q39565401 | ||
| FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. | Q39645996 | ||
| PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. | Q39699582 | ||
| CIP2A expression is elevated in cervical cancer | Q39757518 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | medulloblastoma | Q1333608 |
| xenograft | Q64148587 | ||
| P304 | page(s) | 6913 | |
| P577 | publication date | 2018-05-02 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts | |
| P478 | volume | 8 |
| Q92476256 | Applications of patient-derived tumor xenograft models and tumor organoids |
| Q57062990 | Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth |
| Q92489253 | Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration |
| Q101407729 | Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models |
Search more.